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Patients with dementia and concomitant parkinsonism are frequently encountered in the elderly population. When 
it comes to young adults, however, coexistence of Alzheimer’s disease (AD) and Parkinson’s disease (PD) is rare.  
We described a case of 47-year old man with presenile onset dementia associated with hemiparkinsonism involving 
the right extremities. Brain biopsy showed neurofibrillary tangles and neuritic plaques, compatible with Alzheimer’s 
disease.  Iodine-123  labelled  N-(3-iodopropen-2-yl)-2beta-carbomethoxy-3beta-(4-chlorophenyl)  tropane 
([(123)I]IPT) SPECT, dopamine transporter imaging, revealed a decreased uptake in both basal ganglia, more severe 
on the left side, particularly the caudal putamen, which is consistent with the finding of idiopathic Parkinson’s 
disease. This case is unique in that damage on the nigrostriatal dopaminergic system in a patient with Alzheimer’s 
disease was demonstrated by a functional neuroimaging study and that early-onset AD and early-onset PD, two 
rare conditions, coexist in the same individual.
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Patients with dementia and concomitant parkinsonism 
are frequently encountered in the elderly population. 
There is a long list of differential diagnoses of such a 
syndrome, often causing a major diagnostic challenge in 
clinical practice. However, Alzheimer’s disease (AD) 
and Parkinson’s disease (PD) rarely coexist in young 
adults. 
We describe clinical manifestations along with the 
findings of dopamine transporter SPECT and fluoro-
deoxyglucose (FDG) PET, in a patient with dementia 
and hemiparkinsonism of presenile onset, who was later 
diagnosed of AD based on pathologic findings of brain 
biopsy.
CASE REPORT
A 47-year-old man was referred to the neurology 
clinic for cognitive decline and gait disturbance. At the 
age of 45, he was noted to have easy forgetfulness by 
his family. His memory got gradually worsened and 
speech disturbance developed over the same time period. 
At 46, he had a decreased arm swing and hand dexterity 
on the right side, which kept him from continuing his 
job as a police officer and made him retire early. There 
was no family history of dementia or other neurologic 
illnesses. 
Neurologic examination revealed him to be oriented Journal of Clinical Neurology: Vol. 1, No. 1, 2005
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Figure 1. (A) I-123 IPT dopamine 
transporter image shows a decreased 
uptake in both basal ganglia, more 
severe in the left caudal putamen. 
(B) Brain FDG PET shows a 
markedly decreased uptake in both 
frontal, parietal, and temporal lobes.
Figure 2. (A, B) Brain biopsy shows neurofibrillary tangles and several neuritic plaques on H&E stain and Bielschowsky stain. (C) 
Electron microscopy reveals radiating filamentous structure with surrounding degenerated neurites, compatible with amyloid  plaques.
to person but not to place and time. His facial 
expression was decreased. Speech was dysarthric and 
hypophonic. He could not recall any item after 3 
minutes of encoding. He could draw simple figures such 
as circle or rectangle, but could not make it for more 
complex ones such as copying interlocking pentagons. 
His Mini-Mental state Examination (K-MMSE) score 
was 16. The Korean version of Western Aphasia Battery 
revealed that his speech was nonfluent and effortful with 
some hesitancy. Naming was markedly impaired with 
occasional paraphasic errors and neologism. He could 
only repeat a few words. He had a marked impairment 
in the comprehension of both spoken and written words, 
only obeying one step command. He had cogwheel 
rigidity and hypokinesia in the right upper extremity. 
There was a 6~8 Hz action tremor in the right hand. No 
resting tremor was observed. His gait was short-stepped 
with his right foot dragged and the right arm flexed. A 
decreased arm swing was noted on the right side. His 
Unified Parkinson’s Disease Rating Scale (UPDRS) 
scores were as follows: bradykinesia 2/0, rigidity 2/0, 
resting tremor 0/0, postural tremor 1/0. Hoehn and Yahr 
staging was 1. He did not show myoclonus, apraxia, or 
autonomic dysfunction. Neither cognitive fluctuation nor 
psychiatric symptoms such as visual hallucination and 
delusion were noticed.
All hematological and biochemical laboratory findings 
were normal. Apolipoprotein E genotype was E3/3. 
Brain MRI disclosed diffuse atrophy in both fronto-
temporoparietal areas, more prominent on the left side. 
EEG showed intermittent rhythmic delta slowing in both 
hemispheres. The dopamine transporter image using 
iodine-123 labelled N-(3-iodopropen-2-yl)-2beta-carbo-
methoxy-3beta-(4-chlorophenyl) tropane ([(123)I]IPT) 
SPECT revealed a decreased uptake in both basal 
ganglia, particularly the caudal putamen, more prominent 
on the left side (Fig. 1-A). Brain biopsy was performed 
in left frontal cortex, showing neurofibrillary tangles and 
neuritic plaques, which is compatible with Alzheimer’s 
disease (Fig. 2). No Lewy bodies were found. 
After treatment with donepezil and L-dopa, 
bradykinesia and gait difficulty improved, whereas his 
dementia relentlessly progressed. Brain FDG PET scan, 
3 years after the onset of symptoms, showed markedly 
decreased glucose metabolism in both frontal, parietal, 
and temporal lobes with preserved metabolic activity in Choi EJ, et al. Alzheimer’s disease with parkinsonism 
- 99 -
the primary motor and sensory cortices including 
primary visual cortex, consistent with advanced 
Alzheimer’s disease (Fig. 1-B). Four years after onset of 
dementia, he became bedridden and died of pneumonia 
subsequently.
DISCUSSION
Extrapyramidal symptoms (EPSs) are often presented 
in patients with AD.
1-3 The relationship between EPSs 
and AD is complex and differs depending on the disease 
or the clinical setting. Our patient’s parkinsonism 
developed about 1 year after cognitive impairment and 
was restricted to the right side. In addition, the findings 
of [(123)I]IPT SPECT, dopamine transporter imaging, 
showed a profile of a decreased uptake in the caudal 
putamen, which is typically found in patients with 
idiopathic Parkinson’s disease (IPD). The abnormality of 
dopamine transporter sites was asymmetrical and more 
severe in the left putamen than in the right one, 
compatible with the clinical finding of right hemi-
parkinsonism. The possibility of dementia with Lewy 
bodies (DLB) could be ruled out due to the absence of 
fluctuating cognition and psychiatric manifestations on a 
history and the lack of cortical Lewy bodies on brain 
biopsy. Other differential diagnoses of dementia with 
parkinsonism such as corticobasal degeneration, 
progressive bulbar palsy, multiple system atrophy, 
normal pressure hydrocephalus, or Binswanger’s disease 
were easily excluded based on clinical features and 
neuroimaging changes.
The investigation on damage to the dopamine system 
in IPD, AD, and AD with EPSs revealed different 
patterns among them.
4 In AD, the loss of dopamine 
transporter sites was restricted to nucleus accumbens. In 
AD with EPSs, it was most prominent in the rostral 
caudate and putamen with the caudal striatum least 
affected. On the other hand, in IPD, the caudal striatum 
was the most pronounced area of dopamine transporter 
site loss.
We postulated that our patient has AD and 
concomitant IPD rather than AD with accompanying 
EPSs for the following reasons. First, parkinsonism 
developed after dementia in a short interval when EPSs 
are not usually expected in AD. Secondly, parkinsonism 
of our patient was asymmetric similar to IPD. Thirdly, 
the dopamine transporter image showed a decreased 
uptake in the caudal putamen, which is exactly the same 
as in IPD
.4,5 Finally, our patient responded to anti-
parkinsonian medications. We cannot completely exclude 
the possibility that the EPSs in our patient might be 
simply the manifestation of AD, because the autopsy 
was not performed and the question was unresolved as 
to whether the substantia nigra has NFTs or LBs.
6 So, 
the precise pathogenic mechanism of EPSs of our patient 
remained unanswered. There have been many reports of 
cases in which the pathologic features of both AD and 
PD are encountered in the same individual.
7 Autopsy 
findings revealed that nigral pathology consistent with 
IPD was identified in 80% of patients with AD with 
EPSs, suggesting the common pathogenetic mechanism 
involved in AD and PD.
7
This case is unique in that damage on the nigrostriatal 
dopaminergic system in a patient with Alzheimer’s 
disease was demonstrated by a functional neuroimaging 
study and that early-onset AD and PD, two rare 
conditions, coexist in the same individual.
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